John Wayne Cancer Institute

Summary

John Wayne Cancer Institute is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Breast Cancer, Cancer, Lung Cancer, Brain Tumor and other specialties. John Wayne Cancer Institute is involved with conducting 98 clinical trials across 82 conditions. There are 4 research doctors associated with this hospital, such as Parvin Peddi, MD, Janie G. Weng Grumley, Przemyslaw Twardowski, MD, and Robert Wollman, MD.

Top PIs

Clinical Trials running at John Wayne Cancer Institute

Bladder Cancer

Breast Cancer

Breast cancer

Ovarian Cancer

Cancer

Prostate Cancer

Endometrial Cancer

Solid Tumors

Fallopian Tube Cancer

Peritoneal Carcinoma

Blood Test and Immunotherapy

for Bladder Cancer

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.

Recruiting

1 award

Phase 2 & 3

10 criteria

AU-011 + Laser Therapy

for Bladder Cancer

This trial is testing a new treatment called AU-011 for bladder cancer. The treatment involves injecting the drug directly into the tumor, and sometimes using a laser to make it work better. The goal is to see if this method is safe and effective for patients.

Recruiting

1 award

Phase 1